Methods and compositions for maximum release of oligonucleotides
By using competitive hybridization technology of cleavable sequences and blocking oligonucleotides in the reaction mixture, the problem of oligonucleotide release and allocation in the beads is solved, and efficient increase in bioanalytical data points and enhancement of analysis accuracy is achieved. .
Patent Information
- Application Number
- CN202380027719.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-18
- Filing Date
- 2023-03-16
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art is difficult to effectively release and distribute oligonucleotides from beads, limiting the flexibility of barcode encoding in partitions and increasing data points, affecting the accuracy and efficiency of biological analysis.
By providing a reaction mixture, including covalent linkage of multiple beads to the oligonucleotide, the temperature is controlled to release and partition the oligonucleotide to the partition or 2D by providing a reaction mixture, including multiple beads covalently linked to the oligonucleotide, using a cleavable sequence and blocking competitive hybridization of the oligonucleotide, the temperature is controlled to release and distribute the oligonucleotide to the partition or 2D Arrays ensure non-covalent ligation of the oligonucleotide to the beads, allowing them to exist independently in the partition.
The efficient release and allocation of oligonucleotides in the beads is achieved, the data points in the partition are increased, the accuracy and efficiency of biological analysis are improved, and the inefficiency problem of covalent bond cleavage in the partition is avoided.
Smart Images

Figure CN118922557A_ABST
Abstract
Description
[0001] Cross-reference to related applications
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 321,266, filed on March 18, 2022, which is incorporated herein by reference in its entirety for all purposes.
[0003] Sequence Listing
[0004] The sequence listing conforming to the rules of WIPO Standard ST.26 is hereby incorporated by reference. The sequence listing has been submitted as an electronic document through PatentCenter in ASCII format encoded as XML. The electronic document, created on March 15, 2023, is entitled "094868-1373692-119610PC-ST26.xml" and is 30,907 characters in size. Background Art
[0005] Labeling biological substrates in partitions with molecular barcodes can provide new biological insights into substrates that co-localize to discrete partitions through sequencing of molecular barcodes and their analysis. Increasing the number of barcoded active partitions such as droplets increases the number of sequencing-based data points and converts a larger portion of the input substrate into data. Barcodes can be delivered to partitions such as droplets using beads as delivery vehicles. In order to uniquely identify each partition, beads can be labeled with clonal copies of unique barcode sequences that can be released into the partitions, thereby labeling molecules in the partitions in a partition-specific manner. Summary of the invention
[0006] In some embodiments, a method for releasing an oligonucleotide from a bead is provided. In some embodiments, the method comprises:
[0007] (i) providing a reaction mixture, the reaction mixture comprising:
[0008] a plurality of beads, each bead covalently linked to a first oligonucleotide comprising a first end sequence;
[0009] a second oligonucleotide comprising a second terminal sequence; and
[0010] A connecting oligonucleotide comprising: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence,
[0011] wherein the first terminal sequence and the first end sequence hybridize and have a first melting temperature (Tm), and (ii) the second terminal sequence and the second end sequence hybridize and have a second Tm, such that the linking oligonucleotide links the first oligonucleotide to the second oligonucleotide;
[0012] (ii) raising the temperature of the reaction mixture to above at least one of the first Tm and the second Tm, such that the first oligonucleotide and the second oligonucleotide dissociate from at least one end of the linker oligonucleotide;
[0013] (iii) lowering the temperature of the reaction mixture to below the first Tm and the second Tm,
[0014] wherein after said increasing and before said decreasing, said reaction mixture further comprises a blocking oligonucleotide, said blocking oligonucleotide comprising:
[0015] (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0016] (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0017] (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0018] (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead.
[0019] In some embodiments, the first end sequence is a 3' end sequence. In some embodiments, the first end sequence is a 5' end sequence.
[0020] In some embodiments, the second oligonucleotide has a barcode sequence, wherein an individual bead comprises a cloned copy of the second oligonucleotide, and wherein the barcode sequence of the individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads. In some embodiments, the 3' end of the second oligonucleotide comprises a target-specific sequence. In some embodiments, the 3' end of the second oligonucleotide comprises a universal tag sequence. In some embodiments, the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
[0021] In some embodiments, the providing (i) comprises forming a mixture of beads, wherein each bead is covalently linked to a long oligonucleotide comprising the first oligonucleotide and the second oligonucleotide, wherein the first end sequence of the first oligonucleotide is directly linked to the second end sequence of the second oligonucleotide or indirectly linked through a linker sequence, and wherein the long oligonucleotides on different beads can be distinguished by different barcode sequences in the long oligonucleotides; and hybridizing the connecting oligonucleotide with the long oligonucleotide so that the first end sequence is hybridized with the first end sequence and the second end sequence is hybridized with the second end sequence; and cleaving the long oligonucleotide located between the first end sequence and the second end sequence, while the connecting oligonucleotide remains intact, and connecting the first oligonucleotide to the second oligonucleotide. In some embodiments, the linker sequence comprises one or more uracil nucleotides, and the cleavage comprises contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby removing one or more uracils. In some embodiments, the linker sequence comprises one or more ribonucleotides, and the cleavage comprises cleaving the linker sequence in a ribonucleotide-specific manner using RNAseH. In some embodiments, a restriction site is positioned between the first oligonucleotide and the second oligonucleotide, and the cleaving comprises contacting the long oligonucleotide with a restriction enzyme that cleaves the restriction site on the long oligonucleotide without cleaving the connecting oligonucleotide using a nicking endonuclease.
[0022] In some embodiments, said blocking oligonucleotide is added to said reaction mixture after said cleaving said long oligonucleotide between said first end sequence and said second end sequence.
[0023] In some embodiments, the concentration of the blocking oligonucleotide in the reaction mixture is higher than the concentration of the adapter oligonucleotide in the reaction mixture. In some embodiments, the affinity (Kd) of the blocking oligonucleotide to the first sequence is lower than the affinity of the adapter oligonucleotide to the first sequence.
[0024] In some embodiments, the method further comprises, after said providing (i) and before said increasing (ii), distributing said reaction mixture into a plurality of partitions, wherein different beads in said plurality of beads are delivered into different partitions. In some embodiments, said partitions are micropores, nanopores or droplets.
[0025] In some embodiments, the method further comprises, after said providing (i) and before said increasing (ii), distributing said reaction mixture onto a 2D array, wherein different beads of said plurality of beads are delivered to different locations on said 2D array.
[0026] In some embodiments, a method for forming a cleaved oligonucleotide attached to a bead is provided. In some embodiments, the method comprises: forming a mixture of beads, wherein each bead is covalently attached to a long oligonucleotide comprising a first oligonucleotide and a second oligonucleotide, wherein the first end sequence of the first oligonucleotide is directly attached to the second end sequence of the second oligonucleotide or indirectly attached via a linker sequence, and wherein the long oligonucleotides on different beads can be distinguished by different barcode sequences in the long oligonucleotides; and hybridizing a connecting oligonucleotide to the long oligonucleotide, wherein the connecting oligonucleotide comprises: (i) a first end sequence that is reverse complementary to the first end sequence; and (ii) a second end sequence that is reverse complementary to the second end sequence, wherein the hybridization causes the first end sequence to hybridize to the first end sequence, and the second end sequence to hybridize to the second end sequence; and cleaving the long oligonucleotide located between the first end sequence and the second end sequence, while the connecting oligonucleotide remains intact, and connecting the first oligonucleotide to the second oligonucleotide.
[0027] In some embodiments, the linker sequence includes one or more uracil nucleotides, and the cutting includes contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby excising one or more uracils. In some embodiments, the linker sequence includes one or more ribonucleotides, and the cutting includes using RNAseH to cut the linker sequence in a ribonucleotide-specific manner. In some embodiments, a restriction site is positioned between the first oligonucleotide and the second oligonucleotide, and the cutting includes contacting the long oligonucleotide with a restriction enzyme, which cuts the restriction site on the long oligonucleotide without using a nicking endonuclease to cut the connecting oligonucleotide.
[0028] In some embodiments, a blocking oligonucleotide is added to said reaction mixture after said cleaving said long oligonucleotide between said first end sequence and said second end sequence.
[0029] Also provided is a reaction mixture comprising, for example: a plurality of beads, each bead being covalently linked to a first oligonucleotide comprising a first terminal sequence; a second oligonucleotide, the second oligonucleotide comprising a second terminal sequence; and a linker oligonucleotide comprising: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence; and a blocking oligonucleotide comprising:
[0030] (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0031] (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0032] (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0033] (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead.
[0034] In some embodiments, the first end sequence is a 3' end sequence. In some embodiments, the first end sequence is a 5' end sequence.
[0035] In some embodiments, the second oligonucleotide has a barcode sequence, wherein an individual bead comprises a cloned copy of the second oligonucleotide, and wherein the barcode sequence of the individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads. In some embodiments, the 3' end of the second oligonucleotide comprises a target-specific sequence. In some embodiments, the 3' end of the second oligonucleotide comprises a universal tag sequence. In some embodiments, the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
[0036] In some embodiments, the linker sequence includes one or more uracil nucleotides. In some embodiments, the linker sequence includes one or more ribonucleotides. In some embodiments, the restriction site is located between the first oligonucleotide and the second oligonucleotide.
[0037] Also provided is a kit (eg, a container, optionally with instructions) comprising a plurality of beads as described above or elsewhere herein.
[0038] Also provided is a reaction mixture comprising: a plurality of beads, each bead being covalently linked to a first oligonucleotide comprising a first end sequence; a second oligonucleotide, the second oligonucleotide comprising a second end sequence; and a linking oligonucleotide, the linking oligonucleotide comprising: (i) a first end sequence that is reverse complementary to the first end sequence; and (ii) a second end sequence that is reverse complementary to the second end sequence, wherein the first end sequence hybridizes to the first end sequence and has a first melting temperature (Tm), and (ii) the second end sequence hybridizes to the first end sequence and has a second Tm, such that the linking oligonucleotide links the first oligonucleotide to the second oligonucleotide; wherein the reaction mixture optionally comprises a blocking oligonucleotide, the blocking oligonucleotide comprising:
[0039] (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0040] (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0041] (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or
[0042] (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead.
[0043] In some embodiments, the first end sequence is a 3' end sequence. In some embodiments, the first end sequence is a 5' end sequence.
[0044] In some embodiments, the second oligonucleotide has a barcode sequence, wherein an individual bead comprises a cloned copy of the second oligonucleotide, and wherein the barcode sequence of the individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads. In some embodiments, the 3' end of the second oligonucleotide comprises a target-specific sequence. In some embodiments, the 3' end of the second oligonucleotide comprises a universal tag sequence. In some embodiments, the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
[0045] Also provided is a kit comprising a plurality of beads as described above.
[0046] Also provided is a mixture comprising a plurality of beads, wherein each bead is covalently linked to a hairpin oligonucleotide, wherein the hairpin oligonucleotide comprises, from 5' to 3', a reverse complement of a first sequence, a loop sequence, a first copy of the first sequence, and a second sequence, wherein the reverse complement of the first sequence hybridizes to the first copy of the first sequence and the second sequence is located at the 3' end of the hairpin oligonucleotide, wherein a cleavable sequence is positioned in the reverse complement of the first sequence, in the loop sequence, or in the first copy of the first sequence, wherein the first sequence has a barcode sequence, wherein individual beads comprise a cloned copy of the first sequence, and wherein the barcode sequence of an individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads.
[0047] In some embodiments, the loop sequence further comprises a second copy of the first sequence positioned at the 5' of the cleavable sequence. In some embodiments, the 3' end of the second oligonucleotide comprises a target-specific sequence. In some embodiments, the 3' end of the second oligonucleotide comprises a universal tag sequence. In some embodiments, the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
[0048] In some embodiments, the cleavable sequence comprises one or more uracil nucleotides. In some embodiments, the cleavable sequence comprises one or more ribonucleotides. In some embodiments, the cleavable sequence comprises a restriction site.
[0049] Also provided is a kit comprising a plurality of beads as described above.
[0050] A method of forming a plurality of released oligonucleotides is also provided. In some embodiments, the method comprises: providing a mixture as described above or elsewhere herein; and cleaving the cleavable sequence located 3' of the second copy of the first sequence, while the first copy of the first sequence and the reverse complement of the first sequence remain hybridized, thereby connecting the first copy of the first sequence to the bead by the hybridization.
[0051] In some embodiments, the cleavable sequence includes one or more uracil nucleotides, and the cutting includes contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby excising one or more uracils. In some embodiments, the cleavable sequence includes one or more ribonucleotides, and the cutting includes using RNAseH to cut the joint sequence in a ribonucleotide-specific manner. In some embodiments, the cleavable sequence includes a restriction site, and the cutting includes contacting a nicking endonuclease with the cleavable sequence.
[0052] In some embodiments, the method further comprises distributing the reaction mixture into a plurality of partitions, wherein different beads in the plurality of beads are delivered to different partitions. In some embodiments, the partitions are microwells, nanowells, or droplets. In some embodiments, the method further comprises, after the providing (i) and before the raising (ii), distributing the reaction mixture onto a 2D array, wherein different beads in the plurality of beads are delivered to different locations on the 2D array.
[0053] In some embodiments, the loop sequence further comprises a second copy of the first sequence positioned 5' of the cleavable sequence, and wherein the first copy of the first sequence and the reverse complement of the first sequence have a melting temperature (Tm) when hybridized, and the method further comprises, after the partitioning, (ii) raising the temperature of the reaction mixture to above the Tm such that the first copy of the first sequence dissociates from the reverse complement of the first sequence; (iii) lowering the temperature of the reaction mixture to below the Tm, wherein the second copy of the first sequence competes with the first copy of the first sequence for hybridization with the reverse complement of the first sequence, thereby allowing the oligonucleotide comprising the first copy of the first sequence and the second sequence to remain released from the bead after the lowering.
[0054] In some embodiments, said first copy of said first sequence and said reverse complement of said first sequence have a melting temperature (Tm) upon hybridization, and said method further comprises, after said partitioning, (ii) raising the temperature of said reaction mixture to above said Tm such that said first copy of said first sequence dissociates from said reverse complement of said first sequence; (iii) lowering the temperature of said reaction mixture to below said Tm, wherein after said raising and before said lowering, said mixture further comprises a blocking oligonucleotide comprising a second copy of said first sequence such that said blocking oligonucleotide competes with said first copy of said first sequence for hybridization with said first oligonucleotide, thereby allowing an oligonucleotide comprising said first copy of said first sequence and said second sequence to remain released from said beads after said lowering.
[0055] definition
[0056] Unless otherwise defined, the meaning of all technical terms and scientific terms used herein is generally the same as the meaning generally understood by those of ordinary skill in the art to which the present invention belongs. Generally, the nomenclature used herein and the laboratory procedures in cell culture, molecular genetics, organic chemistry, and nucleic acid chemistry and hybridization described below are well-known and commonly used in the art. Standard techniques are used for nucleic acid and peptide synthesis. Technology and procedures are usually performed according to the conventional methods and various general references in the art (usually referring to, Sambrook et al. "Molecular cloning: Laboratory Manual (MOLECULAR CLONING:ALABORATORY MANUAL)", 2nd edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, the document is incorporated herein by reference), the conventional methods and various general references are provided throughout this document. The nomenclature used herein and the laboratory procedures in analytical chemistry and organic synthesis described below are well-known and commonly used in the art.
[0057] The term "amplification reaction" refers to any in vitro means of amplifying copies of a target sequence of a nucleic acid in a linear or exponential manner. Such methods include, but are not limited to: two-primer methods, such as polymerase chain reaction (PCR); ligase methods, such as DNA ligase chain reaction (see U.S. Pat. Nos. 4,683,195 and 4,683,202; PCR Protocols: A Guide to Methods and Applications (Innis et al., ed., 1990)) (LCR); QBeta RNA replicase and RNA transcription-based amplification reactions (e.g., amplification involving RNA polymerization initiated by T7, T3 or SP6), such as transcription amplification system (TAS), nucleic acid sequence-based amplification (NASBA) and self-sustained sequence replication (3SR); isothermal amplification reactions (e.g., single primer isothermal amplification (SPIA)); and other techniques known to those skilled in the art.
[0058] "Amplification" refers to a step in which a solution is placed under conditions sufficient to amplify a polynucleotide if all components of the reaction are intact. The components of an amplification reaction include, for example, primers, a polynucleotide template, a polymerase, nucleotides, etc. The term "amplification" generally refers to an "exponential" increase in a target nucleic acid. However, as used herein, "amplification" may also refer to a linear increase in the number of a selected target sequence of a nucleic acid, such as obtained by cycle sequencing or linear amplification. In an exemplary embodiment, amplification refers to PCR amplification using a first amplification primer and a second amplification primer.
[0059] "Primer" refers to a polynucleotide sequence that hybridizes with a sequence on a target nucleic acid and serves as a starting point for nucleic acid synthesis. Primers can have various lengths, and the length is generally less than 50 nucleotides, for example, 12 to 30 nucleotides in length. The length and sequence of primers used for PCR can be designed based on principles known to those skilled in the art, see, for example, Innis et al., the same. Primers can be chimeras of DNA, RNA or DNA and RNA portions. In some cases, primers can include one or more modified or non-natural nucleotide bases. In some cases, primers are labeled.
[0060] Nucleic acid or a part thereof "hybridizes" with another nucleic acid under certain conditions, so that non-specific hybridization in physiological buffer (e.g., pH 6-9, 25-150mM chloride salt) at a defined temperature is minimized. In some cases, nucleic acid or a part thereof hybridizes with a conserved sequence common to a group of target nucleic acids. In some cases, if there are at least about 6, 8, 10, 12, 14, 16 or 18 continuous complementary nucleotides, comprising "universal" nucleotides complementary to more than one nucleotide partner, a primer or a part thereof can hybridize with a primer binding site. Alternatively, if there are 0 or less than 2 or 3 complementary mismatches on at least about 12, 14, 16, 18 or 20 continuous nucleotides, a primer or a part thereof can hybridize with a primer binding site. In some embodiments, the defined temperature for specific hybridization is room temperature. In some embodiments, the defined temperature for specific hybridization is higher than room temperature. In some embodiments, the defined temperature for specific hybridization is at least about 37, 40, 42, 45, 50, 55, 60, 65, 70, 75 or 80°C. In some embodiments, the defined temperature at which specific hybridization occurs is 37, 40, 42, 45, 50, 55, 60, 65, 70, 75, or 80°C.
[0061] "Template" refers to a polynucleotide sequence that includes a polynucleotide to be amplified, adjacent to a primer hybridization site, or flanked by a pair of primer hybridization sites. Thus, a "target template" includes a target polynucleotide sequence adjacent to at least one hybridization site for a primer. In some cases, a "target template" includes a target polynucleotide sequence flanked by hybridization sites for a "forward" primer and a "reverse" primer.
[0062] As used herein, "nucleic acid" means DNA, RNA, single-stranded, double-stranded or more highly aggregated hybridization motifs and any chemical modifications thereof. Modifications include, but are not limited to, providing modifications of chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interactions, attachment points, and functionality for nucleic acid ligand bases or for the entire nucleic acid ligand. Such modifications include, but are not limited to, peptide nucleic acids (PNAs), phosphodiester group modifications (e.g., phosphorothioates, methylphosphonates), 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitutions of 4-thiouridine, substitutions of 5-bromine or 5-iodo-uracil; backbone modifications, methylation, unusual base pairing combinations, such as isobases, isocytidines, and isoguanidines, etc. Nucleic acids may also include non-natural bases, such as nitroindole. Modifications may also include 3' and 5' modifications, including, but not limited to, end-capping with fluorophores (e.g., quantum dots) or another portion.
[0063] "Polymerase" refers to an enzyme that performs template-directed synthesis of polynucleotides (e.g., DNA and / or RNA). The term encompasses both full-length polypeptides and domains having polymerase activity. DNA polymerases are well known to those skilled in the art and include, but are not limited to, DNA polymerases isolated or derived from Pyrococcus furiosus, Thermococcus litoralis, and Thermotoga maritime, or modified versions thereof. Additional examples of commercially available polymerases include, but are not limited to, Klenow fragment (New England Biolabs, Inc., Ill.), and the like. Co., Ltd.), Taq DNA polymerase (QIAGEN), 9°N TM DNA polymerase (New England Co., Ltd.), Deep Vent TM DNA polymerase (New England Co., Ltd.), Manta DNA polymerase Bst DNA polymerase (New England Inc.) and phi29 DNA polymerase (New England Biolabs Company Limited).
[0064] Polymerases include both DNA-dependent polymerases and RNA-dependent polymerases, such as reverse transcriptases. It is known that there are at least five DNA-dependent DNA polymerase families, although most belong to A, B and C families. Other types of DNA polymerases include bacteriophage polymerases. Similarly, RNA polymerases generally include eukaryotic RNA polymerases I, II and III, as well as bacterial RNA polymerases and bacteriophage and viral polymerases. RNA polymerases can be DNA-dependent and RNA-dependent.
[0065] As used herein, the term "partition" or "partitioned" refers to separating a sample into multiple parts or "partitions". Partitions are usually physical, so that a sample in one partition will not or substantially will not mix with a sample in an adjacent partition. Partitions can be solid or fluid. In some embodiments, the partition is a solid partition, for example, a microchannel or micropore. In some embodiments, the partition is a fluid partition, for example, a droplet. In some embodiments, the fluid partition (e.g., droplet) is a mixture of immiscible fluids (e.g., water and oil). In some embodiments, the fluid partition (e.g., droplet) is an aqueous droplet surrounded by an immiscible carrier fluid (e.g., oil). Exemplary arrays of holes and hole descriptions can be found in, for example, U.S. Patents Nos. 9,103,754 and 10,391,493. An array of holes (a set of nanopores, micropores, holes) can be used to capture a solid phase carrier, optionally at an addressable known position. Therefore, the array of holes can be configured to facilitate bead capture in at least one solid phase carrier in a single solid phase carrier form or optionally a small group of solid phase carriers. Exemplary microwell arrays and methods of delivering beads to microwells and analysis thereof are described, for example, in PCT / US2021 / 034152.
[0066] As used herein, a "barcode" is a short nucleotide sequence (e.g., at least about 4, 6, 8, 10, 12, 15, 20, 50 or 75 or 100 nucleotides long or longer) that identifies the molecule of the partition to which it is conjugated or from which it is derived. Barcodes can be used, for example, to identify molecules derived from partitions, beads or spots, such as those sequenced later from bulk reactions. Such barcodes may be unique to the partitions, beads or spots compared to barcodes present in other partitions, beads or spots. For example, a partition containing a target RNA from a single cell can be subjected to reverse transcription conditions using primers containing different partition-specific barcode sequences in each partition, thereby incorporating a copy of a unique "cell barcode" (because different cells are in different partitions, and each partition has a unique partition-specific barcode) into the reverse transcribed nucleic acid of each partition. Therefore, due to the unique "cell barcode", nucleic acids from each cell can be distinguished from nucleic acids from other cells. In some embodiments described herein, the barcodes described herein uniquely identify the molecule to which they are conjugated, i.e., the barcodes serve as unique molecular identifiers (UMIs). The length of a possible barcode sequence determines how many unique samples can be distinguished. For example, depending on degeneracy, a 1 nucleotide barcode can distinguish 4 or fewer different partitions; a 4 nucleotide barcode can distinguish 4 4 or 256 partitions or less; a 6-nucleotide barcode can distinguish 4096 different partitions or less; and an 8-nucleotide barcode can index 65,536 different partitions or less.
[0067] As used herein, the terms "a", "an" or "the" include not only aspects having one member, but also aspects having more than one member. For example, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a bead" includes a plurality of such beads, and reference to "the sequence" includes reference to one or more sequences known to those skilled in the art, etc.
[0068] An "oligonucleotide" is a polynucleotide. Typically, an oligonucleotide will have less than 250 nucleotides, in some embodiments, 4-200, such as 10-150 nucleotides.
[0069] A "clonal" copy of a polynucleotide means that the copies are identical in sequence. In some embodiments, at least 100, 1000, 10 4 One or more cloned copies are attached to the beads.
[0070] An "array" is an ordered plurality of items. The term can refer to an ordered plurality of oligonucleotides, or an ordered array attached to an optionally planar solid surface. "Ordered" refers to known positions on the array, and is not intended to indicate a specific alignment of the items, although in some embodiments, the items may be in a grid.
[0071] "3' capture sequence" on an oligonucleotide refers to the 3' most part of the oligonucleotide. The length of the capture sequence can be as little as 1-2 nucleotides, but more typically 6-12 nucleotides in length, and in some embodiments 4-20 or more nucleotides in length. The capture sequence can be fully complementary to the target nucleic acid (e.g., the 3' end of the target nucleic acid), but as understood in some embodiments and under certain conditions, 1, 2, 3, 4 or more nucleotides can be mismatched while still allowing the 3' capture sequence of the oligonucleotide to be bonded to the target nucleic acid. In other embodiments, conditions can be selected so that only fully complementary sequences will bond. The 3' capture sequence can be a random sequence, a poly T or poly A sequence, a target-specific sequence, or a universal sequence. For example, in embodiments where a transposon (e.g., a modified Tn5, such as a tagmentase) inserts an end sequence to sample nucleic acids, the capture 3' end sequence can be complementary to the added end sequence.
[0072] "Labeling" a nucleic acid refers to linking the nucleic acid to another labeling polynucleotide, such as a labeling polynucleotide comprising one or more barcode sequences. Labeling can be covalent (e.g., by attachment or by primer extension) or non-covalent (only by Watson-Crick base pairing).
[0073] The term "bead" refers to any solid support that can be in a partition, such as a small particle or other solid support. Exemplary beads can include hydrogel beads. In some cases, the hydrogel is in the form of a sol. In some cases, the hydrogel is in the form of a gel. An exemplary hydrogel is an agarose hydrogel. Other hydrogels include, but are not limited to, for example, U.S. Patent Nos. 4,438,258; 6,534,083; 8,008,476; 8,329,763; U.S. Patent Application Nos. 2002 / 0,009,591; 2013 / 0,022,569; 2013 / 0,034,592; and International Patent Publication Nos. WO / 1997 / 030092; and WO / 2001 / 049240.
[0074] As used herein, a loop sequence in a hairpin oligonucleotide refers to a portion of the oligonucleotide that is not reverse complementary to other sequences in the oligonucleotide and is located between two reverse complementary portions. See, e.g. Figure 4A The poly T portion is depicted on the right. BRIEF DESCRIPTION OF THE DRAWINGS
[0075] Figure 1 A diagram of a "long" oligonucleotide connected to a bead is depicted (top portion of the accompanying drawing), wherein the long oligonucleotide comprises a first oligonucleotide and a second oligonucleotide sequence separated by a cleavable sequence, in the case depicted, the cleavable sequence is a series of uracils that can be cleaved by a USER enzyme. The bottom portion of the accompanying drawing depicts the same long oligonucleotide sequence hybridized with a connecting oligonucleotide, which is partially hybridized with the first oligonucleotide sequence and the second oligonucleotide sequence. As used herein, the term "oligonucleotide" may refer to a sequence of an oligonucleotide as a part of a longer nucleic acid.
[0076] Figure 2 Depicted with Figure 1 The same molecule shown, but then cut with USER enzyme, to produce the first oligonucleotide connected to the bead but cut from the second oligonucleotide. However, the connecting oligonucleotide remains bonded to both the first oligonucleotide and the second oligonucleotide, thereby preventing the two parts from spreading out relative to each other. As depicted in the accompanying drawings, after cutting the long oligonucleotide, the blocking oligonucleotide is added to the mixture, but as discussed herein, it can be changed when adding the blocking oligonucleotide. The blocking oligonucleotide can be provided with a concentration higher than the concentration of the connecting oligonucleotide and / or can be otherwise modified to have an affinity higher than the affinity of the connecting oligonucleotide, so that after raising and lowering the temperature, for at least one site to which the connecting oligonucleotide hybridizes, the blocking oligonucleotide is a better competitor than the connecting oligonucleotide. Figure 2All actions depicted in can occur in the bulk solution, i.e., before the beads and oligonucleotides attached thereto are moved into partitions or 2D arrays.
[0077] Figure 3 from Figure 2 The above oligonucleotides after being distributed in partitions (e.g., droplets or micropores) or separated on 2D arrays are performed and described. Because the oligonucleotides cut now are connected to beads by connecting oligonucleotides, beads can be delivered to partitions or 2D arrays that have been cut but are still non-covalently connected. Once located in a partition, raising and lowering the temperature will release the second oligonucleotide from the first oligonucleotide by separating the connecting oligonucleotide from one or more of the first and second oligonucleotides, and the blocking oligonucleotide prevents the connecting oligonucleotide from rebonding with at least one of the first and second oligonucleotides by its outstanding competition, thereby allowing the second oligonucleotide to be free in solution, which allows the improved effect of the second oligonucleotide, for example, as a primer or probe of a target nucleic acid.
[0078] 4 depicts an embodiment of a hairpin oligonucleotide in which the first and second oligonucleotides are attached to the bead via a loop sequence and the reverse complement of the first oligonucleotide sequence. Figure 4A An embodiment is depicted in which the cleavable sequence (UUU) is positioned 5' to the loop sequence. Figure 4B An embodiment is depicted in which the cleavable sequence (UUU) is located in the loop sequence. Figure 4C The embodiment described is depicted wherein the cleavable sequence (UUU) is positioned 3' to the loop sequence.
[0079] 5 depicts an alternative hairpin oligonucleotide embodiment in which a first oligonucleotide and a second oligonucleotide are attached to a bead via a variable length sequence, a loop, a reverse complement of the variable length sequence, and a reverse complement of the first oligonucleotide sequence. Figure 5A An embodiment is depicted in which the cleavable sequence (UUU) is positioned 3' to the variable length sequence. Figure 5B An embodiment is depicted in which the cleavable sequence (UUU) is positioned 5' to the reverse complement of the variable length sequence.
[0080] 6 depicts an alternative hairpin oligonucleotide embodiment in which a first oligonucleotide and a second oligonucleotide are attached to a bead via a loop sequence containing a second copy of the first oligonucleotide and the reverse complement of the first oligonucleotide sequence. Fig. 6AAn embodiment is depicted in which the cleavable sequence (UUU) is positioned 3' to the loop sequence. Cleavage of the UUU motif is depicted, followed by intramolecular hybridization between the second copy of the first oligonucleotide sequence and the reverse complement of the first oligonucleotide sequence, and release of the first and second oligonucleotide sequences as 3' to the cleavable sequence. Figure 6B An embodiment is depicted in which the cleavable sequence (UUU) is positioned within the loop sequence but 3' to the second copy of the first oligonucleotide. Figure 6C Depicted Fig. 6A The embodiment of , wherein the short sequence is positioned 5' to the cleavable sequence (UUU), and the reverse complement of the short sequence is positioned 5' to the loop sequence.
[0081] Figure 7 Depict " long " oligonucleotide (top part of accompanying drawing) connected to bead, wherein said long oligonucleotide comprises the first oligonucleotide and the second oligonucleotide sequence separated by a cleavable sequence, in the case of depicting, said cleavable sequence is a series of uracils that can be cut by USER enzyme. Stitching bead base oligonucleotide refers to the sequence that is invariable between beads. Block 1, 2 and 3 refer to 3 variable sequences, which include bead clones but different barcode sequences between beads. Shown are bioanalyzer traces from experiments in which beads are subjected to various conditions in batches. After hybridization with joint sequence + / -, RC, + / -USER cutting, washing beads and + / -heat, collect supernatant and run on gel. The release of full-length oligonucleotide 2 sequence depends on the use of RC, USER and heat.
[0082] Figure 8 Depicted is the release of stitched oligonucleotides compared to USER reagents. The splint oligonucleotides (Tm 62C) were bonded to the stitched beads and then USER digestion was performed in batches. The beads were then aliquoted and incubated at different temperatures. Samples were taken from the supernatant of each aliquot at different time points for ddPCR. For reference, the figure also includes the total number of oligonucleotides on these beads quantified by ddPCR after 1 hour of USER digestion (without splint).
[0083] Fig. 9 Depicted is a comparison of stitched beads versus USER digested beads in a simultaneous protocol as described in Example 3.
[0084] Fig.10 Depicted is a comparison of stitched beads as described in Example 4 relative to USER digested beads. DETAILED DESCRIPTION
[0085] Introduction
[0086] The present disclosure provides methods and compositions for effectively achieving partitioning of bead-attached barcode-encoded oligonucleotides, wherein the barcode-encoded oligonucleotides are ready to be released from the beads once they are in the partitions. The methods allow for providing a mixture of multiple beads, each bead being attached to an oligonucleotide, wherein the mixture can be treated as a bulk solution (before partitioning) to cleave the covalent bonds attaching the oligonucleotides to the beads while maintaining the non-covalent bonds between the beads and the oligonucleotides (by hybridization), thereby allowing the oligonucleotides and the beads to be distributed to partitions or 2D arrays before the oligonucleotides are separated from the beads, for example, in the partitions.
[0087] In some embodiments, the methods described herein involve providing an oligonucleotide covalently linked to a bead, the oligonucleotide comprising a cleavable site on a first strand and a second strand (e.g., a linker oligonucleotide) that is complementary to a sequence on both sides of the first strand adjacent to the cleavable site, such that after the first strand is cleaved (e.g., nicked) at the cleavable site, the second strand continues to link the oligonucleotide to the bead by hybridization of the second strand and two fragments of the first strand as generated by the cleavage. See, e.g., Figure 2 . In these embodiments, the second strand can be independent of the first strand (separated from the first strand), for example, so that if the first strand and the second strand dissociate, the first strand and the second strand will no longer be connected in any way. In other embodiments, the methods described herein relate to providing a hairpin oligonucleotide covalently linked to a bead, the hairpin oligonucleotide comprising a loop sequence, the loop sequence comprising a cleavable site, wherein the reverse complement of the first sequence connected to the bead is separated from the first sequence and optionally another second sequence by the loop sequence. In these embodiments, after cutting the cleavable site, the first (and second (if included)) sequence remains non-covalently linked to the reverse complement of the first sequence by hybridization until it is assigned to a partition or 2D array.
[0088] In any of the embodiments described above, once assigned to a partition or 2D array, the temperature can be raised to dissociate the hybridization sequence, thereby releasing the oligonucleotide from the "stub" sequence remaining on the bead. In order to prevent re-bonding with the stub sequence on the bead once the temperature drops, a blocker oligonucleotide sequence is provided in the partition to act as a competitor to prevent the released oligonucleotide from re-hybridizing with the stub sequence or alternatively connecting the oligonucleotide. The blocker can be an independent molecule from the oligonucleotide, or in some embodiments of the hairpin construct, it can be included as a part of the hairpin sequence itself. Another way to dissociate the hybridization sequence is to use an alkaline pH solution to dissociate the chain, followed by neutralization to allow the hybridization of the blocking oligonucleotide and the subsequent release of the oligonucleotide for the target nucleic acid. For example, on a 2D array, an alkaline pH denaturation of the second oligonucleotide can be performed, followed by the addition of a pH neutralization buffer to allow the hybridization and extension of the release oligonucleotide, for example, to barcode the target nucleic acid. In another example, the alkaline solution can be delivered to the droplet by co-flowing the alkaline solution during droplet formation, followed by neutralization by, for example, adding a neutralizing agent or solution to the droplet by a microfluidic method. Methods and compositions for delivering agents to one or more partitions include microfluidic methods as known in the art; droplet or microcapsule assembly, coalescence, fusion, rupture or degradation (e.g., as described in US2015 / 0027,892; US2014 / 0227,684; WO 2012 / 149,042; and WO 2014 / 028,537); droplet injection methods (e.g., as described in WO 2010 / 151,776); and combinations thereof.
[0089] As mentioned above, the advantage of the embodiments described herein is that the oligonucleotides connected with beads can be generated in batches, processed in batches by the method described herein, and then assigned to the partition or otherwise assigned in the 2D array, at which point the oligonucleotides can be dissociated with the beads. It can be seen that by removing the covalent bond of the oligonucleotide from the beads (a part of the oligonucleotide remains on the beads), the oligonucleotides covalently connected with the beads can still be delivered to the partition or the 2D array, without having to cut the covalent bond in the partition or the 2D array. This is useful, at least because the method for covalent bond cutting in the partition or the 2D array may introduce low efficiency.
[0090] The first nucleic acid chain and the second nucleic acid chain can be provided as a separate chain, or it can be covalently linked by a hairpin sequence. In some embodiments described herein, the method is related to the use of oligonucleotides non-covalently linked to beads (that is, cut as described herein) to generate free oligonucleotides. These methods can be performed in batches or in partitions or in 2D arrays, but as described herein, the benefit is to perform these steps in partitions or in 2D arrays. In other embodiments described herein, the method is related to starting with the oligonucleotides covalently linked to beads, and batch generation of oligonucleotide colonies non-covalently linked to beads.
[0091] In some embodiments, the nucleic acid strands that will serve as linker oligonucleotides are initially separate independent molecules in a mixture, and the linker oligonucleotides will bind to the short column sequence on the bead (i.e., the portion of the oligonucleotide that remains covalently attached to the bead after cleavage, see e.g., Figure 7 In this context, "separate and independent" means that the nucleic acid strand is not covalently linked to the short column sequence or the remaining oligonucleotide sequence. Figure 1 An example of such a configuration is depicted in the upper portion of , where the top sequence is attached to the beads. Located between the underlined sequences are three uracils (U) representing one possible type of cleavable sequence. The underlined sequences (labeled "first end sequence" and "second end sequence") are directly reverse complementary to the individual oligonucleotides below, allowing the individual oligonucleotides (also referred to herein as "connecting oligonucleotides") to hybridize with the depicted first and second oligonucleotide sequences, thereby non-covalently linking the two sequences.
[0092] Although connecting oligonucleotide respectively with the first end sequence of the first oligonucleotide and the second end sequence hybridization of the second oligonucleotide, the middle cleavable sequence can be cut.As discussed in more detail below, the mode of the nucleic acid chain that cleavable sequence and cutting contain cleavable sequence can change.Yet, by cutting cleavable sequence, the first oligonucleotide sequence and the second oligonucleotide sequence only keep together by the non-covalent hybridization of connecting oligonucleotide.
[0093] Therefore, in some embodiments, oligonucleotides in the following form can be generated: the first oligonucleotide sequence and the second oligonucleotide sequence are only kept together by the non-covalent hybridization of the following connection oligonucleotides.In certain embodiments, a mixture of beads is formed, wherein each bead is covalently connected to a "long" oligonucleotide including the first oligonucleotide and the second oligonucleotide sequence, wherein the first end sequence of the first oligonucleotide is directly connected to the second end sequence of the second oligonucleotide or is indirectly connected by a joint sequence.In this context, "long" only means that the oligonucleotide includes both the first oligonucleotide sequence and the second oligonucleotide sequence and the middle cleavable sequence, and is therefore longer than any single sequence alone.Connection oligonucleotides are provided or added to the mixture together with the mixture so that the first end sequence is hybridized with the first end sequence and the second end sequence is hybridized with the second end sequence because they appear in long oligonucleotides.Hybridization conditions can be easily determined based on, for example, precise sequence hybridization and pH and salt concentration.Once hybridized, the long oligonucleotide chain is cut at the cleavable sequence (between the first end sequence and the second end sequence), and the connection oligonucleotide remains intact and the first oligonucleotide is connected to the second oligonucleotide by hybridization.
[0094] The cleavable sequence can be any cleavable sequence that can be targeted enzymatically or otherwise while leaving the remaining nucleic acid sequences in the mixture (e.g., the linking oligonucleotide and the first and second oligonucleotides) intact. The cleavage of the cleavable sequence preferably occurs in a bulk solution, wherein the plurality of beads and their linked oligonucleotides are together in one solution, i.e., before partitioning or otherwise spatially distributing them.
[0095] In some embodiments, the cleavable sequence includes one or more uracils. For example, the cleavable sequence can include 1, 2, 3, 4 or more uracils, which can be continuous. The uracils can be selectively removed and the backbone can be cleaved (nicked) by contacting the backbone with uracil DNA glycosylase and endonuclease VIII that excises one or more uracils. Uracil DNA glycosylase and endonuclease VIII can be, for example, in the form of "USER TM "(uracil-specific excision reagent) was commercially obtained from New England Biolabs.
[0096] In some embodiments, the cleavable sequence includes one or more ribonucleotides. For example, the cleavable sequence can include 1, 2, 3, 4 or more ribonucleotides, which can be continuous. This allows the use of enzymes that selectively cut ribonucleotides and do not substantially cut deoxyribonucleotides. For example, in some embodiments, RNAseH is used to specifically cut at the ribonucleotides in the cleavable sequence.
[0097] In some embodiments, the cleavable sequence includes a restriction enzyme recognition or cleavage site (collectively referred to as a "restriction site") located between the first oligonucleotide and the second oligonucleotide. In these embodiments, the long oligonucleotide can be cleaved with a restriction enzyme that cleaves the restriction site on the long oligonucleotide without cleaving the connecting oligonucleotide. Examples of such enzymes include endonucleases. Preferably, the restriction enzyme is selected so that its recognition and / or cleavage site only appears in the cleavable sequence and does not appear elsewhere in the oligonucleotides in the mixture.
[0098] In some embodiments, the oligonucleotide of non-covalent connection can be distributed to the partition or 2D array by the user.In some embodiments, the oligonucleotide of non-covalent connection and the bead are generated by the user (for example, as discussed above), and in other embodiments, they are provided to the user (for example, from a commercial supplier).In any option, the user can distribute the oligonucleotide of bead and non-covalent connection in the partition or on the 2D array (for example, surface).The distribution of the oligonucleotide of bead and non-covalent connection in the partition can be realized by any available method.For example, the partition can be formed in advance with other reagents and the target nucleic acid optionally from the biological sample, and the oligonucleotide of bead and non-covalent connection can be injected or otherwise introduced in the partition. Methods and compositions for delivering agents to one or more partitions include microfluidic methods as known in the art; droplet or microcapsule assembly, coalescence, fusion, rupture or degradation (e.g., as described in US2015 / 0027,892; US2014 / 0227,684; WO 2012 / 149,042; and WO 2014 / 028,537); droplet injection methods (e.g., as described in WO2010 / 151,776); and combinations thereof.
[0099] In other embodiments, for example, where the partitions are droplets, the droplets can be formed as an emulsion with an immiscible fluid (such as oil) so that the bulk solution forms droplets containing beads and non-covalently attached oligonucleotides, optionally with other reagents and / or sample nucleic acid. For example, methods of emulsion formation are described in published patent applications WO 2011 / 109546 and WO 2012 / 061444.
[0100] In some embodiments, the distribution of beads into partitions (e.g., droplets) can be determined by Poisson distribution. Depending on the end use, the average number of beads per partition can be less than 1 (e.g., 0.2-0.9), 1 or greater than 1 (e.g., 1-3 or greater). In some embodiments, it is desirable to avoid multiple beads in partitions, and in these cases, many partitions can be left empty so that most partitions containing beads contain only one bead. In other embodiments, for example, where a deconvolution method can be used to decrypt sequencing results in which multiple beads appear in a single partition, each partition can be loaded with more beads on average, and then deconvolution is used to parse the sequencing results. See, for example, PCT / US2017 / 012618, PCT / US2019 / 015638, PCT / US2020 / 36699. In some embodiments, the beads and associated oligonucleotides are partitioned into at least 500 partitions, at least 1000 partitions, at least 2000 partitions, at least 3000 partitions, at least 4000 partitions, at least 5000 partitions, at least 6000 partitions, at least 7000 partitions, at least 8000 partitions, at least 10,000 partitions, at least 15,000 partitions, at least 20,000 partitions, at least 30,000 partitions, at least 40,000 partitions, at least 50,000 partitions, at least 60,000 partitions, at least 70,000 partitions, at least 80, ...90,000 partitions, at least 10,000 partitions, at least 15,000 partitions, at least 20,000 partitions, at least 30,000 partitions, at least 30,000 partitions, at least 50,000 partitions, at least 60,000 partitions, at least 70,000 partitions, at least 80,000 partitions, at least 80,000 partitions, at least 10,000 partitions, at least 10,000 partitions, at least 15,000 partitions, at least 20,000 partitions, at least 30,000 partitions 00 partitions, at least 40,000 partitions, at least 50,000 partitions, at least 60,000 partitions, at least 70,000 partitions, at least 80,000 partitions, at least 90,000 partitions, at least 100,000 partitions, at least 200,000 partitions, at least 300,000 partitions, at least 400,000 partitions, at least 500,000 partitions, at least 600,000 partitions , at least 700,000 partitions, at least 800,000 partitions, at least 900,000 partitions, at least 1,000,000 partitions, at least 2,000,000 partitions, at least 3,000,000 partitions, at least 4,000,000 partitions, at least 5,000,000 partitions, at least 10,000,000 partitions, at least 20,000,000 partitions, at least 30,000 ,000 partitions, at least 40,000,000 partitions, at least 50,000,000 partitions, at least 60,000,000 partitions, at least 70,000,000 partitions, at least 80,000,000 partitions, at least 90,000,000 partitions, at least 100,000,000 partitions, at least 150,000,000 partitions, or at least 200,000,000 partitions.
[0101] In certain embodiments, after beads and non-covalently linked oligonucleotides are distributed in partitions, non-covalently linked oligonucleotides can be released from beads, for example, before oligonucleotides are attached to barcodes, primer extension is performed to perform other purposes of oligonucleotides. Non-covalently linked oligonucleotides can be released from beads and can be related to non-covalently linked oligonucleotides being exposed to conditions that dissociate the hybridization part. This can be achieved, for example, by increasing the temperature to a melting temperature Tm higher than the hybridization sequence. In the embodiment where there is a joint oligonucleotide, the first end sequence of the joint sequence and the first end sequence of the first oligonucleotide are hybridized and have a first melting temperature (Tm), and (ii) the second end sequence of the joint oligonucleotide and the second end sequence are hybridized and have a second Tm, so that the joint oligonucleotide connects the first oligonucleotide to the second oligonucleotide. In these embodiments, the reaction mixture temperature can be increased to a melting temperature higher than at least one of the first or second Tm. In certain embodiments, Tm is within 10 or 5 degrees, so that the mixture temperature is increased to a Tm higher than Tm and the temperature is also increased to a temperature higher than another Tm, so that two groups of hybridization sequences are dissociated.
[0102] Before the temperature is lowered to below a Tm (or multiple Tms), the blocking oligonucleotide can be introduced into the mixture. The blocking oligonucleotide can be introduced into the mixture earlier in the process, for example, at any time in the above-mentioned sequence of events, including when the mixture is formed for the first time, but should exist before the temperature is lowered. As discussed in more detail below, in the embodiment in which the hairpin oligonucleotide is adopted and in the embodiment in which the blocking competition function is provided by the intramolecular sequence, it is not necessary to provide a blocking oligonucleotide at all. However, when present, the blocking oligonucleotide will compete with one of the oligonucleotides to be released or the remaining short column sequence present on the bead to be combined. In either case, by bonding with a sequence in these sequences, the released oligonucleotide will remain free of beads and will not be bonded again. In certain embodiments, the blocking oligonucleotide will be provided with a concentration higher than the concentration of the released oligonucleotide, thereby allowing the blocking oligonucleotide to better compete for binding. In certain embodiments, the blocking oligonucleotide can have one or more non-natural nucleotides, so that the affinity of the sequence bonded by it is stronger than the affinity of the released oligonucleotide (Kd is lower).
[0103] The blocking oligonucleotide can be configured in four alternatives to compete with and prevent the released oligonucleotide from reattaching to the short column sequence back to the bead:
[0104] (a) In some embodiments, the blocking oligonucleotide includes a sequence of more than 2, 3, 4, or 5 contiguous nucleotides that is reverse complementary to the first end sequence but does not include a sequence that is reverse complementary to the second end sequence (i.e., such that it does not "bridge" the first oligonucleotide and the second oligonucleotide), such that the blocking oligonucleotide competes with the connecting oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to retain the sequence released from the bead.
[0105] (b) In some embodiments, the blocking oligonucleotide includes a sequence of 2, 3, 4, or 5 consecutive nucleotides that are reverse complementary to the second end sequence but not to the first end sequence, such that the blocking oligonucleotide competes with the connecting oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to retain the sequence released from the bead.
[0106] (c) In some embodiments, the blocking oligonucleotide includes a sequence of more than 2, 3, 4, or 5 consecutive nucleotides as the first end sequence but not in the second end sequence, such that the blocking oligonucleotide competes with the connecting oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to retain the sequence released from the bead.
[0107] (d) In some embodiments, the blocking oligonucleotide includes a sequence of more than 2, 3, 4, or 5 consecutive nucleotides as the second end sequence but does not include a sequence as the first end sequence, such that the blocking oligonucleotide competes with the connecting oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to retain the sequence released from the bead.
[0108] Hairpin
[0109] In some embodiments, a separate linking oligonucleotide is not employed or required because the initial oligonucleotide attached to the bead is a hairpin having a self-complementary sequence and thus attached to itself. In some embodiments, the bead is covalently attached to a hairpin oligonucleotide comprising, from 5' to 3', the reverse complement of a first sequence, a loop sequence comprising a cleavable sequence, a first copy of the first sequence, and a second sequence, wherein the reverse complement of the first sequence hybridizes to the first copy of the first sequence, and the second sequence is located at the 3' end of the hairpin oligonucleotide. Examples of this embodiment can be found, for example, in Figure 4B In some embodiments, the loop sequence further includes a second copy of the first sequence (see, e.g., FIG. 6 ), and in some embodiments, the loop sequence does not include a second copy of the first sequence (e.g., Figure 4A -C and Figure 5A -B). In some embodiments, the cleavable sequence is located within the reverse complement of the first sequence (e.g., Figure 5B ), 5' of the loop sequence (e.g., Figure 4A ), within the ring sequence ( Figure 4B), 3' of the loop sequence ( Figure 4C ) and / or in the first sequence ( Figure 5A ). When the loop sequence includes a second copy of the first sequence, the cleavable sequence is located 3' to the second copy of the first sequence ( Fig. 6A -C).
[0110] In any embodiment, a plurality of beads attached to a hairpin oligonucleotide can be provided in batches, and the cleavable sequence can be cleaved to produce a portion of the cleaved hairpin oligonucleotide comprising the reverse complement of the first sequence still covalently attached to the bead and a second portion of the cleaved hairpin oligonucleotide comprising a first copy of the first sequence and a second sequence. The second portion in these embodiments is no longer covalently attached to the bead, but is non-covalently attached to the bead by hybridization of the first copy of the first sequence with the reverse complement of the first sequence. See, e.g., Figure 4A -C. The cleavable sequence and its cleavage can be achieved as discussed above.
[0111] Once cut, for example, in a bulk mixture, the beads and their non-covalently linked portions can be distributed into partitions or onto a 2D array. A distributed non-covalently linked oligonucleotide portion (e.g., in a partition or onto a 2D array) can be released, for example, by raising the temperature to a Tm higher than the first copy of the first sequence relative to the reverse complement of the first sequence. As discussed above for different configurations, blocking oligonucleotides can be introduced into the mixture before the temperature is lowered to less than the Tm. Blocking oligonucleotides can be introduced into the mixture earlier in the process, for example, at any time in the above sequence of events, including when the mixture is formed for the first time, but should exist before the temperature is lowered. The blocking oligonucleotide will compete for binding to one of the following: (1) the first copy of the first sequence; or (2) the reverse complement of the first sequence. In either case, by bonding to one of these sequences, the released oligonucleotide will remain bead-free and will not rebond. In some embodiments, the blocking oligonucleotide will be provided at a concentration higher than the concentration of the released oligonucleotide, thereby allowing the blocking oligonucleotide to better compete for binding. In some embodiments, the blocking oligonucleotide may have one or more non-natural nucleotides such that the affinity of the sequence to which it binds is stronger (lower Kd) than that of the released oligonucleotide.
[0112] In yet another embodiment, the hairpin oligonucleotide comprises a loop sequence that further comprises a second copy of the first sequence (see, e.g., FIG. 6 ). As described above for other hairpin oligonucleotide configurations, this configuration can be employed, but without the need to utilize a blocking oligonucleotide, because the second copy of the first sequence is used to compete with the re-hybridization (re-bonding) of the first copy of the first sequence with the reverse complement of the first sequence. In addition, because this reaction is intramolecular, the second copy of the first sequence is covalently attached to the reverse complement of the first sequence, and therefore the second copy of the first sequence should outcompete the released portion of the hairpin oligonucleotide comprising the first copy of the first sequence, thereby allowing the released portion to remain free in solution. See, e.g., Fig. 6A .
[0113] In any of the embodiments described herein, the oligonucleotides attached to the beads may include one or more barcode nucleotide sequences. In some embodiments, the oligonucleotides include a barcode sequence that is unique to the beads to which they are attached, and thus can be used, for example, to distinguish the oligonucleotides from different beads after the oligonucleotides are released and to generate sequencing reads. Additional barcodes, such as but not limited to unique molecular identifiers (UMIs) or sample-specific barcodes, may also be included in the oligonucleotide sequence, i.e., in the portion of the oligonucleotide that is ultimately released in the partition or onto the 2D array.
[0114] Beads with any available size and composition for delivery to partitions or 2D arrays can be used. Particles or beads can be any particles or beads with a solid phase carrier surface. Solid phase carriers suitable for particles include controlled pore glass (CPG) (available from Glen Research, Sterling, Va.), oxalyl controlled pore glass (see, for example, Alul et al., "Nucleic Acids Research" 1991, 19, 1527), TentaGel carrier-a kind of amino polyethylene glycol derivative carrier (see, for example, Wright et al., "Tetrahedron Letters" 1993, 34, 3373), polystyrene, Poros (copolymer of polystyrene / divinylbenzene) or reversibly cross-linked acrylamide. Many other solid carriers are commercially available and suitable for the present invention. In certain embodiments, the bead material is polystyrene resin or poly (methyl methacrylate) (PMMA). The bead material can be metal.
[0115] In some embodiments, the particles or beads include a hydrogel or another similar composition. In some cases, the hydrogel is in the form of a sol. In some cases, the hydrogel is in the form of a gel. An exemplary hydrogel is an agarose hydrogel. Other hydrogels include, but are not limited to, for example, U.S. Patent Nos. 4,438,258; 6,534,083; 8,008,476; 8,329,763; U.S. Patent Application Nos. 20020009591; 20130022569; 20130034592; and International Patent Publication No. WO1997030092; and the hydrogels described in No. WO2001049240. Additional compositions and methods for making and using hydrogels (such as barcoded hydrogels) include, for example, those described in Klein et al., Cell, 2015 May 21;161(5):1187-201.
[0116] The solid support surface of the beads can be modified to include a linker for connecting the barcode oligonucleotide. The linker can include a cleavable portion. Non-limiting examples of cleavable portions include disulfide bonds, dioxyuridine moieties, and restriction enzyme recognition sites.
[0117] Oligonucleotide can be connected to beads as needed. The method of connecting oligonucleotide to beads is described in, for example, WO2015 / 200541. In certain embodiments, the oligonucleotide configured to connect hydrogel beads to barcodes is covalently linked to the hydrogel. Many methods for covalently linking oligonucleotide to one or more hydrogel matrices are known in the art. As an example, agarose derivatized with aldehydes can be covalently linked to the 5'-amine group of synthetic oligonucleotides.
[0118] One is delivered to a partition or 2D array, and in the presence of a target (e.g., sample) nucleic acid, the oligonucleotide released from the bead can be used to perform primer extension or other hybridization-based reactions. In some embodiments, the 3' end sequence of the oligonucleotide is directly bonded to the target nucleic acid. For example, if the target nucleic acid is mRNA, the 3' end sequence can be a poly dT sequence (e.g., 6-20 consecutive dT nucleotides), or the 3' end can contain a poly (e.g., a random sequence of 6-10 or more nucleotides) to randomly pre-infuse the target, or the 3' end sequence can have gene specificity to specifically amplify one or more target nucleic acids. In some embodiments, the 3' sequence of the oligonucleotide is bonded to a universal sequence on the target nucleic acid. For example, a tag can cause an adapter sequence to be inserted into the end of a fragmented nucleic acid, and the 3' end can be reverse complementary to the adapter sequence.
[0119] In some embodiments, once the oligonucleotides are released into the partition or on the 2D array, they can be used, for example, to amplify the sample nucleic acid in the partition or on the 2D array by extension of the 3' end of the oligonucleotide, for example, by copying portions of the sample nucleic acid by a polymerase, thereby labeling the sample nucleic acid with an oligonucleotide sequence, the oligonucleotide sequence can preferably include one or more barcode sequences as described herein (e.g., bead-specific barcode sequences). The amplified sequence can then be used as needed. In some embodiments, the amplified cDNA can be cloned into a vector or otherwise deployed into a cDNA library, which can optionally be stored and replicated as needed.
[0120] In some embodiments, the amplified nucleic acid can be subjected to nucleotide sequencing. Once the nucleic acid has been labeled with an oligonucleotide, the labeled nucleic acid can be prepared as needed for nucleotide sequencing. For example, universal primer sequences (a universal primer sequence) can be added at both ends of the labeled sequence. As long as at least some of the DNA segment sequence and the barcode sequence are determined, any nucleotide sequencing method can be used as needed. Methods for high-throughput sequencing and genotyping are known in the art. For example, such sequencing techniques include but are not limited to pyrophosphate sequencing, connection sequencing, single molecule sequencing, synthetic sequence (SBS), massively parallel cloning, massively parallel single molecule SBS, massively parallel single molecule real-time, massively parallel single molecule real-time nanopore technology, etc. Morozova and Marra provide a review of some such techniques in Genomics, 92:255 (2008), which is incorporated herein by reference as a whole.
[0121] Exemplary DNA sequencing techniques include fluorescence-based sequencing methods (see, e.g., Birren et al., Genome Analysis: Analyzing DNA, 1, Cold Spring Harbor Laboratory, New York; the document is incorporated herein by reference in its entirety). In some embodiments, automated sequencing techniques as understood in the art are utilized. In some embodiments, the present technology provides parallel sequencing of partitioned amplicons (PCT Publication No. WO 2006 / 084132, the document is incorporated herein by reference in its entirety). In some embodiments, DNA sequencing is achieved by parallel oligonucleotide extension (see, e.g., U.S. Pat. Nos. 5,750,341; and 6,306,597, both of which are incorporated herein by reference in their entirety). Additional examples of sequencing techniques include: Church polony technology (Mitra et al., 2003, Analytical Biochemistry). Biochemistry, 320, 55-65; Shendure et al., 2005 Science, 309, 1728-1732; and U.S. Pat. Nos. 6,432,360; 6,485,944; and 6,511,803; the entireties of which are incorporated herein by reference); 454 pico-titer pyrosequencing (Margulies et al., 2005 Nature, 437, 376-380; U.S. Publication No. 2005 / 0130173; the entireties of which are incorporated herein by reference); S olexa single base addition technology (Bennett et al., 2005, Pharmacogenomics, 6,373-382; U.S. Pat. Nos. 6,787,308; and 6,833,246; the entireties of which are incorporated herein by reference); Lynx massively parallel tag sequencing technology (Brenner et al. (2000). Nature Biotechnology 18:630-634; U.S. Pat. Nos. 5,695,934; and 5,714,330; the entireties of which are incorporated herein by reference); and Adessi PCR colony technology (Adessi et al. (2000). Nucleic Acids Research 28, E87; WO 2000 / 018957; the entireties of which are incorporated herein by reference).
[0122] In general, high-throughput sequencing methods share the common features of massively parallel high-throughput strategies, and the goal is to reduce costs compared to older sequencing methods (see, e.g., Voelkerding et al., Clinical Chem., 55:641-658, 2009; MacLean et al., Nature Rev. Microbiol., 7:287-296; each of which is incorporated herein by reference in its entirety). Such methods can be broadly divided into methods that generally use template amplification and methods that do not use template amplification. Methods that require amplification include pyrophosphate sequencing commercialized by Roche as 454 technology platforms (e.g., GS20 and GS FLX), Solexa platforms commercialized by Illumina, and supported oligonucleotide ligation and detection (SOLiD) platforms commercialized by Applied Biosystems. Non-amplification methods, also known as single-molecule sequencing, are exemplified by the HeliScope platform commercialized by Helicos BioSciences and platforms commercialized by VisiGen, Oxford Nanopore Technologies Ltd., Life Technologies / Ion Torrent, and Pacific Biosciences, respectively.
[0123] The practice of the present invention can employ conventional methods of chemistry, biochemistry, molecular biology, cell biology, genetics, immunology and pharmacology, which are within the skill of the art. Such techniques are fully explained in the literature. See, e.g., Gennaro, AR, ed. (1990) Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co.; Hardman, JG, Limbird, LE, and Gilman, AG, eds. (2001) The Pharmacological Basis of Therapeutics, 10th ed., McGraw-Hill Co.; Colowick, S. et al., eds., Methods In Enzymology, Academic Press, Inc.; Weir, DM and Blackwell, CC, eds. (1986) Handbook of Experimental Immunology, Vols. I-IV, Blackwell Scientific Publishers. =Scientific Publications); Maniatis, T. et al., eds. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Vols. I-III, Cold Spring Harbor Laboratory Press; Ausubel, FM et al., eds. (1999-2010) Current Protocols in Molecular Biology, John Wiley & Sons; Ream et al., eds. (1998) Molecular Biology Techniques: An Intensive Laboratory Course, Academic Press; Newton, CR and Graham, A., eds. (1997) PCR (Introduction to Biotechniques Series), 2nd ed., Springer Verlag; Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed.) (1989).
[0124] Any type of partition can be used with the methods and compositions described herein. In certain embodiments, beads can be inserted into partitions (e.g., droplets or holes). In certain embodiments, beads are encapsulated in aqueous droplets in water-in-oil emulsions. For example, methods and compositions for partitioning samples are described in published patent applications WO 2010 / 036,352, US2010 / 0173,394, US2011 / 0092,373 and US2011 / 0092,376, each of which is incorporated herein by reference in its entirety. Multiple mixture partitions can be located in multiple emulsion droplets or multiple micropores, etc. Partitions can be picopores, nanopores or micropores. In certain embodiments, there are at least, for example, 100,000 holes or 200,000 holes, for example, 100,000-500,000 holes. The volume capacity of exemplary holes can be, for example, 10-50 picoliters. Exemplary wells include those described in U.S. Patent Publication No. US2021 / 0283608. The mixture partition may be a picochamber, a nanochamber, or a microreaction chamber, such as a picocapsule, a nanocapsule, or a microcapsule. The mixture partition may be a picochannel, a nanochannel, or a microchannel. The mixture partition may be a droplet, for example, an emulsion droplet.
[0125] As described herein, in some embodiments, beads and non-covalently linked oligonucleotides are distributed on 2D arrays. The method of generating an array of oligonucleotides with known sequences is known and can be used to generate arrays as described herein. See, for example, US2021 / 0332351 and US2020 / 0299322 or as described in addition by, for example, DNA Script or Twist Biosciences. These methods can, for example, provide spatially addressable oligonucleotides on a planar array, thereby meaning that the oligonucleotide sequence at each point on the array is known. In certain embodiments, such planar carriers have a plurality of sites, and the plurality of sites include at least 256 sites, at least 512 sites, at least 1024 sites, at least 5000 sites, at least 10,000 sites, at least 25,000 sites or at least 100,000 sites and up to 10,000,000 sites. In certain embodiments, the area of each discrete site of the synthesis of the occurrence point is in the range of 0.25 μm 2 Up to 1000μm 2 , or 1μm 2 Up to 1000μm 2 , or 10μm 2 Up to 1000μm 2 , or 100μm 2 Up to 1000μm 2In some embodiments, the amount of polynucleotide synthesized at each point is at least 10 -6 fmol, or at least 10 -3 fmol, or at least 1 fmol, or at least 1 pmol, or the amount of polynucleotide synthesized at each point ranges from 10 -6 fmol to 1fmol, or 10 -3 fmol to 1fmol, or 1fmol to 1pmol, or 10 -6 pmol to 10 pmol, or 10 -6 In some embodiments, the number of polynucleotides synthesized at each point ranges from 1000 molecules to 10 6 molecules, or 1000 molecules to 10 9 molecules, or 1000 molecules to 10 12 In some embodiments, the array is on a flow cell.
[0126] In some embodiments, the methods described herein can be used for spatial analysis. Spatial analysis is a method for highly multiplexed spatial analysis of proteins or RNA of samples that are fixed with formalin and embedded in paraffin (FFPE). See, for example, Beecham, Methods Mol Biol. 2055: 563-583 (2020). In some embodiments, the methods described herein allow for improved spatial analysis methods by using in situ labeling in fixed (e.g., FFPE) tissue samples. After in situ labeling of nucleic acids in tissue samples, tissues can be contacted with beads connected to cloned barcode encoding oligonucleotides. Alternatively, tissues can be contacted with released barcode encoding oligonucleotides from beads near the tissue.
[0127] Examples
[0128] Example 1 (predictive):
[0129] Twenty-three micrometer diameter clonal barcode gel beads with hairpin oligonucleotides terminated with oligo dT sequences and including three uracil nucleotides in the loop sequence were incubated in batches at 37°C for 30 minutes with USER enzymes including uracil DNA glycosylase and endonuclease VIII. Uracil nucleotides were cleaved from the clonal oligonucleotides. Due to the T sequence of its double-stranded hybridization mThe temperature is about 60°C, so the hybridization of the sequence at 5' upstream of the loop sequence and the sequence at 3' downstream of the loop sequence is maintained, whereby the loop sequence contains a cleaved uracil nucleotide. Therefore, even if the loop sequence is cleaved, the 3'-cleaved oligonucleotide containing the barcode and the oligonucleotide dT priming sequence is still non-covalently linked to the beads by hybridizing with the remaining oligonucleotides connected to the beads. Blocker oligonucleotides complementary to the hybridized portion of the remaining oligonucleotides connected to the beads are added in batches to a concentration of 5 μM. The beads and blocker oligonucleotides are loaded into a microwell with a diameter of 25 microns together with the cells so that only one bead can fit into the well. Cells are loaded with a λ of <0.06 so that most wells have one cell or no cells. Reverse transcriptase is warmed up, and a buffer containing 0.5% NP-40 for lysing cells is flowed through the space above the microwell. After allowing diffusion into the microwell, the well is sealed with oil by flowing oil through the microwell. The temperature of the chip is then raised to 70°C, which is sufficient not only to warm up the reverse transcriptase, but also to denature the 3' oligonucleotides cut from the remaining oligonucleotides attached to the beads. The temperature is then lowered to 42°C, allowing the blocker to hybridize with the remaining oligonucleotides on the gel beads. Due to the hybridization of the blocker oligonucleotide, the released 3' barcode oligonucleotide remains in solution. The reaction is maintained at 42°C for 60 minutes. When the cells have been lysed with the lysis reagent, reverse transcription occurs through the sensitized 3' cut barcode dT oligonucleotide. After the reverse transcription step, the oil is removed from the microwells and the cDNA is retrieved from the chip. Sample preparation and sequencing is followed by single-cell analysis of the barcode sequences grouped and attributed to individual partitions and single cells.
[0130] Example 2:
[0131] The base bead oligonucleotides of Example 2-4 are as follows:
[0132] TTTTTTACGGTAGCAGAGACTTGGTCTUUUCTACACGCCTGTCCG
[0133] CGGAAGCAGTGGTATCAACGC
[0134] After the gel beads are generated with the base bead oligonucleotides integrated into the matrix, the barcode sequence and template attachment sequence are added, resulting in the full-length bead oligonucleotide sequence.
[0135] The following splint oligonucleotides were used in this experiment, Splint Oligonucleotide 1:
[0136] GCGGACAGGCGTGTAGAAAAGACCAAGTCTCTGCTACCG
[0137] By mixing the splint oligonucleotide with 500,000 base beads, then incubating at 95C for 5 minutes and then slowly cooling to room temperature by removing the incubation tube from the heat source, an excess (i.e., 2 nanomoles) of splint oligonucleotide 1 with a Tm of 62°C was bonded to the base oligonucleotide. After the oligonucleotides were bonded, USER from NEB was added to the bead mixture, followed by incubation at 37°C to digest the U in the base oligonucleotide. The beads were then washed to remove the USER enzyme. The bead slurry was then distributed into different tubes, and the tubes were incubated at the following temperatures: 25°C, 55°C, and 70°C. After the bead slurry was mixed to ensure homogenization, a small amount of supernatant aliquots were removed at the following time points and subjected to ddPCR quantification: 5 minutes, 30 minutes, 60 minutes, 6 hours, and 24 hours. As a positive control, the splint-minus condition was performed in parallel to determine how many oligonucleotides could be released to the maximum extent. Since the Tm of the sequence flanking U is above 25°C, the complex remains stable, with minimal oligonucleotide release detected at 25°C at all time points, reaching approximately 5% of the control after 24 hours. At 55C incubation temperature, release increased from approximately 20% of the control to 50% at the maximum time. As expected, at 70°C, the amount of released bead oligonucleotide was roughly equal to the positive control at all time points measured, since the Tm of the splint oligonucleotide is greatly exceeded at this temperature. See Figure 8 . These data support the conclusion that the splint oligonucleotide is fully bonded to the base oligonucleotide. USER cleavage is effective in removing U from the base oligonucleotide splint complex. Under low temperature incubation below Tm, the cleaved base oligonucleotide splint complex is stable. Under high temperature incubation, the bead oligonucleotide is maximally released from the cleaved base-splint oligonucleotide complex.
[0138] Example 3:
[0139] The following splint oligonucleotides were used in this experiment, splint oligonucleotide 2:
[0140] GCAGGCGTGTAGAAAAGACCAAGTCTCTG
[0141] The splint oligonucleotide No. 2 with a Tm of 50°C is bonded to the base oligonucleotide connected to the mixture of 55 million beads. The bonding step is achieved by the same method as described in Example 2. Then, USER is added, and the mixture is incubated at 37°C to digest the U in the base oligonucleotide. After the splint-base oligonucleotide complex is formed and USER is cut, the beads are washed, and about 10,000 beads are removed from the mixture and divided equally. About 10,000 cells are added to the aliquoted beads, followed by a reverse transcription master mix containing reverse transcriptase and a cleavage reagent. The contents are mixed thoroughly. The reaction mixture is incubated at 50°C to achieve some oligonucleotide release (in the case of a splint Tm of 50°C, only about 50% of the oligonucleotides are expected to be released, provided that USER cutting is effective) and reverse transcription. An aliquot of the mixture is removed, and the GAPDH bead oligonucleotide templated cDNA molecules are quantified by ddPCR. This was achieved by using ddPCR primers targeting the bead oligo consensus 5' sequence on one side of the amplicon and the GAPDH sequence on the other side. In parallel, the same procedure was performed on beads lacking the splint oligo. This constituted a positive control as all bead barcode oligos were expected to be maximally released. The ddPCR measurements showed that the splint oligo condition achieved approximately 40% conversion of the GAPDH bead oligo cDNA compared to the control, as expected since the Tm of the splint oligo bead complex was similar to the Tm of the reverse transcription incubation temperature. See Fig. 9 These data indicate that USER digestion of the splint base bead oligonucleotide complex was efficient and released approximately half of the oligonucleotides to perform reverse transcription in the mixture. Furthermore, the data indicate that the reaction mixture is a viable solution to simultaneously release oligonucleotides, lyse cells, and perform reverse transcription in solution.
[0142] Example 4:
[0143] The following splint oligonucleotides were used in this experiment, splint oligonucleotide 3 (Tm 68°C):
[0144] CGCGGACAGGCGTGTAGAAAAGACCAAGTCTCTGCTACCGTAAA
[0145] Using splint oligonucleotide 3, a similar procedure to that described in Example 3 was followed in Example 4 until the step of aliquoting the 10,000 beads and cells. Oligonucleotide release, cleavage, and reverse transcription were performed sequentially rather than simultaneously. USER was added first to cleave U in the bead oligonucleotide. The cells were then lysed by adding a cleavage reagent and incubated on ice for 1 hour while allowing RNA to hybridize to the bead oligonucleotide. The beads were then washed to remove USER and cleavage reagent, followed by the addition of a reverse transcription master mix and reverse transcriptase. The mixture was incubated at 50°C for 1 hour to activate reverse transcription, followed by a 15 minute step at 65°C to release the oligonucleotide. GAPDH was measured by ddPCR as described in Example 3. As a positive control, the splint oligonucleotide was omitted from the procedure and USER was added during the reverse transcription step. ddPCR of cDNA labeled with the bead oligonucleotide showed that reverse transcription driven by the released bead oligonucleotide in solution was as efficient as the positive control. See Fig.10 This suggests that the oligonucleotide is stable after USER cleavage and that subsequent release of the oligonucleotide with heat is efficient. Together, these data indicate functionality of the stitched bead oligonucleotide and its release by heat in a sequential cell lysis-reverse transcription approach.
[0146] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, those skilled in the art will appreciate that certain changes and modifications may be implemented within the scope of the appended claims. In addition, each reference provided herein is incorporated herein by reference in its entirety to the same extent as if each reference were incorporated by reference individually.
Claims
1. A method for releasing an oligonucleotide from a bead, the method comprising: (i) providing a reaction mixture, the reaction mixture comprising: a plurality of beads, each bead covalently linked to a first oligonucleotide comprising a first end sequence; a second oligonucleotide comprising a second terminal sequence; and A connecting oligonucleotide comprising: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence, wherein the first terminal sequence and the first end sequence hybridize and have a first melting temperature (Tm), and (ii) the second terminal sequence and the second end sequence hybridize and have a second Tm, such that the linking oligonucleotide links the first oligonucleotide to the second oligonucleotide; (ii) raising the temperature of the reaction mixture to above at least one of the first Tm and the second Tm, such that the first oligonucleotide and the second oligonucleotide dissociate from at least one end of the linker oligonucleotide; (iii) lowering the temperature of the reaction mixture to below the first Tm and the second Tm, wherein after said increasing and before said decreasing, the reaction mixture further comprises a blocking oligonucleotide comprising: (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead. The method according to claim 1 , wherein the first end sequence is a 3′ end sequence. The method according to claim 1 , wherein the first end sequence is a 5′ end sequence.
4. The method of claim 1, wherein the second oligonucleotide has a barcode sequence, wherein individual beads comprise cloned copies of the second oligonucleotide, and wherein the barcode sequence of an individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads. The method of claim 4 , wherein the 3′ end of the second oligonucleotide comprises a target-specific sequence. The method of claim 4 , wherein the 3′ end of the second oligonucleotide comprises a universal tag sequence. The method of claim 4 , wherein the 3′ end of the second oligonucleotide comprises at least 4 consecutive thymines.
8. The method of claim 1, wherein the providing (i) comprises forming a mixture of beads, wherein each bead is covalently linked to a long oligonucleotide comprising the first oligonucleotide and the second oligonucleotide, wherein the first end sequence of the first oligonucleotide is directly linked to the second end sequence of the second oligonucleotide or indirectly linked through a linker sequence, and wherein the long oligonucleotides on different beads can be distinguished by different barcode sequences in the long oligonucleotides; and hybridizing the linking oligonucleotide to the long oligonucleotide such that the first end sequence hybridizes to the first end sequence and the second end sequence hybridizes to the second end sequence; and The long oligonucleotide located between the first end sequence and the second end sequence is cleaved while the linking oligonucleotide remains intact, and the first oligonucleotide is linked to the second oligonucleotide.
9. The method of claim 8, wherein the linker sequence comprises one or more uracil nucleotides, and the cleavage comprises contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby excising one or more uracils.
10. The method of claim 8, wherein the linker sequence comprises one or more ribonucleotides, and the cleavage comprises cleaving the linker sequence in a ribonucleotide-specific manner using RNAseH.
11. The method of claim 8, wherein a restriction site is positioned between the first oligonucleotide and the second oligonucleotide, and the cleavage comprises contacting the long oligonucleotide with a restriction enzyme that cleaves the restriction site on the long oligonucleotide without using a nicking endonuclease to cleave the connecting oligonucleotide.
12. The method according to any one of claims 9 to 11, wherein the blocking oligonucleotide is added to the reaction mixture after the cleavage of the long oligonucleotide located between the first end sequence and the second end sequence.
13. The method according to any one of claims 1 to 11, wherein the concentration of the blocking oligonucleotide in the reaction mixture is higher than the concentration of the adapter oligonucleotide in the reaction mixture.
14. The method of any one of claims 1 to 13, wherein the blocking oligonucleotide has a lower affinity (Kd) for the first sequence than the adapter oligonucleotide has for the first sequence.
15. The method according to any one of claims 1 to 14, further comprising, after said providing (i) and before said increasing (ii), distributing the reaction mixture into a plurality of partitions, wherein different beads among the plurality of beads are delivered to different partitions. The method of claim 15 , wherein the partition is a microwell, a nanowell, or a droplet.
17. The method according to any one of claims 1 to 14, further comprising, after said providing (i) and before said raising (ii), distributing the reaction mixture onto a 2D array, wherein different beads among said plurality of beads are delivered to different positions on said 2D array.
18. A method of forming a cleaved oligonucleotide attached to a bead, the method comprising forming a mixture of beads, wherein each bead is covalently linked to a long oligonucleotide comprising a first oligonucleotide and a second oligonucleotide, wherein a first end sequence of the first oligonucleotide is directly linked to a second end sequence of the second oligonucleotide or is indirectly linked via a linker sequence, and wherein the long oligonucleotides on different beads can be distinguished by different barcode sequences in the long oligonucleotides; as well as hybridizing a linking oligonucleotide to the long oligonucleotide, wherein the linking oligonucleotide comprises: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence, wherein the hybridization causes the first terminal sequence to hybridize to the first terminal sequence, and the second terminal sequence to hybridize to the second terminal sequence; and The long oligonucleotide located between the first end sequence and the second end sequence is cleaved while the linking oligonucleotide remains intact, and the first oligonucleotide is linked to the second oligonucleotide.
19. The method of claim 18, wherein the linker sequence comprises one or more uracil nucleotides, and the cleavage comprises contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby excising the one or more uracils.
20. The method of claim 18, wherein the linker sequence comprises one or more ribonucleotides, and the cleavage comprises cleaving the linker sequence in a ribonucleotide-specific manner using RNAseH.
21. The method of claim 18, wherein a restriction site is positioned between the first oligonucleotide and the second oligonucleotide, and the cleavage comprises contacting the long oligonucleotide with a restriction enzyme that cleaves the restriction site on the long oligonucleotide without cleaving the linking oligonucleotide using a nicking endonuclease.
22. The method according to any one of claims 18 to 21, wherein a blocking oligonucleotide is added to the reaction mixture after said cleavage of said long oligonucleotide between said first end sequence and said second end sequence.
23. A reaction mixture comprising: a plurality of beads, each bead covalently linked to a first oligonucleotide comprising a first end sequence; a second oligonucleotide comprising a second terminal sequence; as well as A linking oligonucleotide comprising: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence; and A blocking oligonucleotide, the blocking oligonucleotide comprising: (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead.
24. The reaction mixture of claim 23, wherein the first end sequence is a 3' end sequence.
25. The reaction mixture of claim 23, wherein the first end sequence is a 5' end sequence.
26. A reaction mixture according to claim 23, wherein the second oligonucleotide has a barcode sequence, wherein individual beads include cloned copies of the second oligonucleotide, and wherein the barcode sequence of an individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads.
27. The reaction mixture of claim 26, wherein the 3' end of the second oligonucleotide comprises a target-specific sequence.
28. The reaction mixture of claim 26, wherein the 3' end of the second oligonucleotide comprises a universal tag sequence.
29. The reaction mixture of claim 26, wherein the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
30. The reaction mixture of claim 23, wherein the linker sequence comprises one or more uracil nucleotides.
31. The reaction mixture of claim 23, wherein the linker sequence comprises one or more ribonucleotides.
32. The reaction mixture of claim 23, wherein a restriction site is located between the first oligonucleotide and the second oligonucleotide.
33. A kit comprising the plurality of beads of any one of claims 23 to 32.
34. A reaction mixture comprising: a plurality of beads, each bead covalently linked to a first oligonucleotide comprising a first end sequence; a second oligonucleotide comprising a second terminal sequence; as well as A connecting oligonucleotide comprising: (i) a first terminal sequence that is reverse complementary to the first terminal sequence; and (ii) a second terminal sequence that is reverse complementary to the second terminal sequence, wherein the first terminal sequence hybridizes to the first end sequence and has a first melting temperature (Tm), and (ii) the second terminal sequence hybridizes to the first end sequence and has a second Tm, such that the linking oligonucleotide links the first oligonucleotide to the second oligonucleotide; wherein the reaction mixture optionally includes a blocking oligonucleotide comprising: (a) a sequence that is reverse complementary to the first end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the second end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (b) a sequence that is reverse complementary to the second end sequence but does not include more than 3 consecutive nucleotides that are reverse complementary to the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (c) a sequence that is more than 3 consecutive nucleotides in the first end sequence but does not include the second end sequence, such that the blocking oligonucleotide competes with the linker oligonucleotide for hybridization with the first oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead; or (d) a sequence that is the second end sequence but does not include more than 3 consecutive nucleotides that is the first end sequence, such that the blocking oligonucleotide competes with the linking oligonucleotide for hybridization with the second oligonucleotide, thereby allowing the second oligonucleotide to remain released from the bead.
35. The reaction mixture of claim 34, wherein the first end sequence is a 3' end sequence.
36. The reaction mixture of claim 34, wherein the first end sequence is a 5' end sequence.
37. A reaction mixture according to claim 34, wherein the second oligonucleotide has a barcode sequence, wherein individual beads include cloned copies of the second oligonucleotide, and wherein the barcode sequence of an individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads.
38. The reaction mixture of claim 37, wherein the 3' end of the second oligonucleotide comprises a target-specific sequence.
39. The reaction mixture of claim 37, wherein the 3' end of the second oligonucleotide comprises a universal tag sequence.
40. The reaction mixture of claim 37, wherein the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
41. A kit comprising the plurality of beads of any one of claims 34 to 40.
42. A mixture comprising a plurality of beads, wherein each bead is covalently linked to a hairpin oligonucleotide, the hairpin oligonucleotide comprising, from 5' to 3', a reverse complement of a first sequence, a loop sequence, a first copy of the first sequence, and a second sequence, wherein the reverse complement of the first sequence hybridizes to the first copy of the first sequence, and the second sequence is located at the 3' end of the hairpin oligonucleotide, wherein a cleavable sequence is located in said reverse complement of said first sequence, in said loop sequence or in said first copy of said first sequence, wherein the first sequence has a barcode sequence, wherein individual beads comprise clonal copies of the first sequence, and wherein the barcode sequence of an individual bead is unique such that the barcode distinguishes the bead from other beads in the plurality of beads.
43. The mixture of claim 42, wherein the loop sequence further comprises a second copy of the first sequence positioned 5' to the cleavable sequence.
44. The mixture of claim 42 or 43, wherein the 3' end of the second oligonucleotide comprises a target specific sequence.
45. The mixture of claim 42 or 43, wherein the 3' end of the second oligonucleotide comprises a universal tag sequence.
46. The mixture of claim 42 or 43, wherein the 3' end of the second oligonucleotide comprises at least 4 consecutive thymines.
47. The mixture of any one of claims 42 to 46, wherein the cleavable sequence comprises one or more uracil nucleotides.
48. The mixture of any one of claims 42 to 46, wherein the cleavable sequence comprises one or more ribonucleotides.
49. The mixture of any one of claims 42 to 46, wherein the cleavable sequence comprises a restriction site.
50. A kit comprising the plurality of beads of any one of claims 42 to 49.
51. A method of forming a plurality of released oligonucleotides, the method comprising: Providing a mixture according to any one of claims 42 to 49; as well as The cleavable sequence located 3' of the second copy of the first sequence is cleaved, while the first copy of the first sequence and the reverse complement of the first sequence remain hybridized, thereby linking the first copy of the first sequence to the bead by the hybridization.
52. The method of claim 51, wherein the cleavable sequence comprises one or more uracil nucleotides, and the cleavage comprises contacting the long oligonucleotide with uracil DNA glycosylase and endonuclease VIII, thereby excising the one or more uracils.
53. The method of any one of claims 42 to 46, wherein the cleavable sequence comprises one or more ribonucleotides and the cleavage comprises cleaving the linker sequence in a ribonucleotide-specific manner using RNAseH.
54. The method of any one of claims 42 to 46, wherein the cleavable sequence comprises a restriction site and the cleavage comprises contacting a nicking endonuclease with the cleavable sequence.
55. The method of claim 51, further comprising partitioning the reaction mixture into a plurality of partitions, wherein different beads of the plurality of beads are delivered to different partitions.
56. The method of claim 55, wherein the partition is a microwell, a nanowell, or a droplet.
57. The method of claim 55, further comprising, after said providing (i) and before said raising (ii), distributing the reaction mixture onto a 2D array, wherein different beads among said plurality of beads are delivered to different positions on said 2D array.
58. The method of any one of claims 51 to 57, wherein the loop sequence further comprises a second copy of the first sequence positioned 5' to the cleavable sequence, and wherein the first copy of the first sequence and the reverse complement of the first sequence have a melting temperature (Tm) upon hybridization, and the method further comprises, after the partitioning, (ii) raising the temperature of the reaction mixture to above the Tm such that the first copy of the first sequence dissociates from the reverse complement of the first sequence; (iii) reducing the temperature of the reaction mixture to below the Tm, wherein the second copy of the first sequence competes with the first copy of the first sequence for hybridization with the reverse complement of the first sequence, thereby allowing the oligonucleotide comprising the first copy of the first sequence and the second sequence to remain released from the beads after the reduction.
59. The method of any one of claims 51 to 57, wherein the first copy of the first sequence and the reverse complement of the first sequence have a melting temperature (Tm) when hybridized, and the method further comprises, after the partitioning, (ii) raising the temperature of the reaction mixture to above the Tm such that the first copy of the first sequence dissociates from the reverse complement of the first sequence; (iii) reducing the temperature of the reaction mixture to below the Tm, wherein after said increasing and before said decreasing, said mixture further comprises a blocking oligonucleotide comprising a second copy of said first sequence, such that said blocking oligonucleotide competes with said first copy of said first sequence for hybridization with said first oligonucleotide, thereby allowing an oligonucleotide comprising said first copy of said first sequence and said second sequence to remain released from said beads after said decreasing.
